The Manufacturers Life Insurance Company Lowers Stock Position in Elanco Animal Health Incorporated $ELAN

Key Points

• The Manufacturers Life Insurance Company reduced its stake in Elanco Animal Health by 7.3%, owning approximately 1.29% of the company after selling 508,385 shares.
• Elanco Animal Health reported $1.24 billion in revenue for the most recent quarter, surpassing analysts' estimates, and earnings per share of $0.26, beating expectations by $0.06.
• Analysts have a positive outlook on Elanco Animal Health, with an average target price of $17.33, and ratings showing one "Strong Buy," five "Buy," and three "Hold" ratings.

The Manufacturers Life Insurance Company decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 7.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,415,713 shares of the company's stock after selling 508,385 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 1.29% of Elanco Animal Health worth $67,365,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its stake in Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock valued at $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Elanco Animal Health by 1.9% in the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company's stock worth $167,826,000 after purchasing an additional 292,655 shares during the period. Shapiro Capital Management LLC increased its stake in Elanco Animal Health by 7.5% in the fourth quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock worth $149,640,000 after purchasing an additional 862,900 shares during the period. Nuveen LLC purchased a new stake in Elanco Animal Health in the first quarter worth $115,212,000. Finally, Douglas Lane & Associates LLC lifted its holdings in shares of Elanco Animal Health by 5.6% in the 1st quarter. Douglas Lane & Associates LLC now owns 3,895,190 shares of the company's stock worth $40,899,000 after buying an additional 205,241 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

Shares of ELAN traded up $0.12 during trading hours on Thursday, reaching $17.47. 2,978,698 shares of the company traded hands, compared to its average volume of 5,998,302. The stock has a market capitalization of $8.68 billion, a P/E ratio of 20.32, a P/E/G ratio of 3.41 and a beta of 1.62. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.87. The business has a fifty day moving average price of $15.81 and a 200-day moving average price of $12.83.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

ELAN has been the subject of several research reports. Piper Sandler upped their target price on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, August 11th. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a report on Thursday, July 17th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Finally, UBS Group lifted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.